Brigitte C. Widemann | |
|---|---|
 Widemann in 2001 | |
| Scientific career | |
| Fields | Pediatric oncology |
| Institutions | National Cancer Institute |
Brigitte C. Widemann is German-American pediatric oncologist. She is chief of the pediatric oncology branch and clinical deputy director of the center for cancer research at the National Cancer Institute. She is also the special advisor to the NCI director for childhood cancer.
Widemann is a pediatric oncologist specialized in developing therapies for children and adults with genetic tumor predisposition syndromes, such as neurofibromatosis type I (NF1), and rare solid tumors. [1] She completed a pediatric residency at the University of Cologne. [1] Widemann then moved to the National Institutes of Health (NIH) for a pediatric hematology and oncology fellowship in the Pediatric Oncology Branch of the National Cancer Institute (NCI). [1] She conducted research in the Pharmacology and Experimental Therapeutics Section (PETS), where she studied antimetabolites and had a leadership role in the clinical development of glucarpidase, a rescue agent for patients who experience renal failure after administration of high-dose methotrexate. [1]
Widemann established a clinical research program to study the natural history of NF1 and develop clinical trials for patients with peripheral nerve sheath tumors. [1] After a series of clinical trials, Widemann’s team led the phase II registration trial of the MEK inhibitor selumetinib, which resulted in the first ever Food and Drug Administration (FDA) approval of a medical therapy for NF1 related inoperable plexiform neurofibromas in children with NF1. [1] Widemann expanded these efforts to other rare tumors and is a founding member of the NCI Rare Tumor Initiative and a co-leader on the Cancer Moonshot funded My Pediatric and Adult Rare Tumor Network (MyPART). [1] Widemann heads the Pharmacology & Experimental Therapeutics Section, as Chief of NCI’s Pediatric Oncology Branch, and as a clinical Deputy Director of the Center for Cancer Research (CCR). [1] She is the special advisor to the NCI director for childhood cancer. [1]
Widemann and her team were finalists for the 2021 Samuel J. Heyman Service to America Medal under the science and environment category. [2]
The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship.
A neurofibroma is a benign nerve-sheath tumor in the peripheral nervous system. In 90% of cases, they are found as stand-alone tumors, while the remainder are found in persons with neurofibromatosis type I (NF1), an autosomal-dominant genetically inherited disease. They can result in a range of symptoms from physical disfiguration and pain to cognitive disability.
The Children's Oncology Group (COG), a clinical trials group supported by the National Cancer Institute (NCI), is the world's largest organization devoted exclusively to pediatric cancer research. The COG conducts a spectrum of clinical research and translational research trials for infants, children, adolescents, and young adults with cancer.
The European Organisation for Research and Treatment of Cancer (EORTC) is a unique pan-European non-profit clinical cancer research organisation established in 1962 operating as an international association under Belgium law. It develops, conducts, coordinates and stimulates high-quality translational and clinical trial research to improve the survival and quality of life of cancer patients. This is achieved through the development of new drugs and other innovative approaches, and the testing of more effective therapeutic strategies, using currently approved drugs, surgery and/or radiotherapy in clinical trials conducted under the auspices of a vast network of clinical cancer researchers supported by 220 staff members based in Brussels. The EORTC has the expertise to conduct large and complex trials especially specific populations such as the older patient and rare tumours.
Cancer and Leukemia Group B is a cancer research cooperative group in the United States.
Yale Cancer Center (YCC) was founded in 1974 as a result of an act of Congress in 1971, which declared the nation's "war on cancer". It is one of a network of 56 Comprehensive Cancer Centers designated by the National Cancer Institute (NCI). Currently directed by Dr. Eric Winer, the Cancer Center brings together the resources of the Yale School of Medicine (YSM), Yale New Haven Hospital (YNHH), and the Yale School of Public Health (YSPH).
Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:
Hope & Heroes is a 501(c)(3) non-profit organization based at Columbia University Medical Center (CUMC) in New York City. Hope & Heroes supports the Division of Pediatric Hematology, Oncology & Stem Cell Transplantation at Columbia University Medical Center. Hope & Heroes funds work on childhood cancer and blood disorders at Columbia University Medical Center—including research, support for families, and care.
The Alliance for Clinical Trials in Oncology is a national clinical trials network sponsored by the National Cancer Institute (NCI) that consists of about 10,000 cancer specialists at hospitals, medical centers, and community clinics across the United States and Canada. The Alliance develops and conducts clinical trials with promising new cancer therapies, and utilizes scientific research to develop treatment and prevention strategies for cancer, as well as researching methods to alleviate side effects of cancer and cancer treatments.
Professor Minesh P. Mehta, MD, FASTRO, is an American radiation oncologist and physician-scientist of Indian origin, Ugandan birth, Zambian Schooling and American Training, who contributed to the field of oncology for more than two and half decades.
Thomas E. Hutson is an American medical oncologist and cancer researcher based in Dallas, Texas. He is the director of Genitourinary Oncology Program and co-director of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center. He is a Professor of Medicine at the Texas A&M Health Science Center College of Medicine and serves as a chair of Genitourinary Research for US Oncology and McKesson.
Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.
Elizabeth Ruth Plummer is a Professor of Experimental Cancer Medicine at Newcastle University and an oncologist specialising in treating patients with melanoma. Based in Newcastle, she directs the Sir Bobby Robson Cancer Trials Research Centre, set up by the Sir Bobby Robson Foundation to run early-stage clinical trials.v Plummer and the Newcastle team won a 2010 Translational Cancer Research Prize from Cancer Research UK for work using rucaparib to treat ovarian cancer. Plummer was elected as a fellow of the UK's Academy of Medical Sciences in 2018.
Brigid Gray Leventhal was a British-American pediatric oncologist. She was the first director of the Pediatric Oncology Division at Johns Hopkins University, a position she held from 1976 to 1984. She was inducted into the Maryland Women's Hall of Fame in 1996.
Andrea B. Apolo is an American medical oncologist specialized in bladder cancer research. She is an investigator in the National Cancer Institute's genitourinary malignancies branch and head of the bladder cancer section.
Rosandra N. Kaplan is an American pediatric oncologist and scientist specialized in translational and clinical research on the mechanisms of cancer spread. She is a principal investigator and head of the tumor microenvironment and metastasis branch at the National Cancer Institute.
Amy K. LeBlanc is an American veterinary oncologist and biologist researching animal modeling for development of new cancer drugs and imaging agents, and identification of imaging biomarkers, development and optimization of PET imaging hardware and imaging protocols. She is a senior scientist in the molecular imaging program and director of the Comparative Oncology Program at the National Cancer Institute. LeBlanc was previously an associate professor at the University of Tennessee College of Medicine and College of Veterinary Medicine.
Nirali N. Shah is an American physician-scientist and pediatric hematologist-oncologist, serving as head of the hematologic malignancies section of the pediatric oncology branch at the National Cancer Institute. She researches the translation of immunotherapeutic approaches to treat high-risk hematologic malignancies in children, adolescents and young adults.
Nilofer Saba Azad is an American oncologist and physician-scientist specialized in gastrointestinal, colorectal, cholangiocarcinoma, and pancreaticobiliary cancers. She is a professor at the Johns Hopkins School of Medicine and oversees clinical trials at the Sidney Kimmel Comprehensive Cancer Center.
Sharon A. Savage is an American pediatric hematologist/oncologist. She is the clinical director of the National Cancer Institute's Division of Cancer Epidemiology and Genetics.
This article incorporates text from this source, which is in the public domain : "Staff Directory: Brigitte C. Widemann, M.D." National Cancer Institute . Retrieved 2022-09-03. This article incorporates public domain material from websites or documents of the National Institutes of Health.| International | |
|---|---|
| National | |
| Academics | |
